The DOI matches its Crossref record; 153 of the 153 references it cites were found in a registry or an index.
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Open accessAbstract
Histone deacetylase (HDAC) inhibitors are an emerging class of therapeutics with potential as anticancer drugs. The rationale for developing HDAC inhibitors (and other chromatin-modifying agents) as anticancer therapies arose from the understanding that in addition to genetic mutations, epigenetic changes such as dysregulation of HDAC enzymes can alter phenotype and gene expression, disturb homeostasis, and contribute to neoplastic growth. The family of HDAC inhibitors is large and diverse. It includes a range of naturally occurring and synthetic compounds that differ in terms of structure, function, and specificity. HDAC inhibitors have multiple cell type-specific effects in vitro and in vivo, such as growth arrest, cell differentiation, and apoptosis in malignant cells. HDAC inhibitors have the potential to be used as monotherapies or in combination with other anticancer therapies. Currently, there are two HDAC inhibitors that have received approval from the US FDA for the treatment of cutaneous T-cell lymphoma: vorinostat (suberoylanilide hydroxamic acid, Zolinza) and depsipeptide (romidepsin, Istodax). More recently, depsipeptide has also gained FDA approval for the treatment of peripheral T-cell lymphoma. Many more clinical trials assessing the effects of various HDAC inhibitors on hematological and solid malignancies are currently being conducted. Despite the proven anticancer effects of particular HDAC inhibitors against certain cancers, many aspects of HDAC enzymes and HDAC inhibitors are still not fully understood. Increasing our understanding of the effects of HDAC inhibitors, their targets and mechanisms of action will be critical for the advancement of these drugs, especially to facilitate the rational design of HDAC inhibitors that are effective as antineoplastic agents. This review will discuss the use of HDAC inhibitors as multitargeted therapies for malignancy. Further, we outline the pharmacology and mechanisms of action of HDAC inhibitors while discussing the safety and efficacy of these compounds in clinical studies to date.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Kornberg, R. D. (1974) · Science · doi:10.1126/science.184.4139.868 · Cited by 2,650
Activation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Bernstein, B. E., Meissner, A., & Lander, E. S. (2007) · Cell · doi:10.1016/j.cell.2007.01.033 · Cited by 2,086
Molecular regulation of angiogenesis and lymphangiogenesis
Adams, R. H., & Alitalo, K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2183 · Cited by 2,019
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Roth, S. Y., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,845
Acetylation and deacetylation of non-histone proteins
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005) · Gene · doi:10.1016/j.gene.2005.09.010 · Cited by 1,584
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Kornberg, R. D. (1977) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.46.070177.004435 · Cited by 1,296
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X.-J., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,230
Duration of Nuclear NF-κB Action Regulated by Reversible Acetylation
Chen, L.-F., Fischle, W., Verdin, E., & Greene, W. C. (2001) · Science · doi:10.1126/science.1062374 · Cited by 1,222
Marks, P. A., & Breslow, R. (2007) · Nature Biotechnology · doi:10.1038/nbt1272 · Cited by 1,196
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
Class II Histone Deacetylases Act as Signal-Responsive Repressors of Cardiac Hypertrophy
Zhang, C. L., McKinsey, T. A., Chang, S., Antos, C. L., Hill, J. A., & Olson, E. N. (2002) · Cell · doi:10.1016/s0092-8674(02)00861-9 · Cited by 973
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis
Vega, R. B., Matsuda, K., Oh, J., Barbosa, A. C., Yang, X., Meadows, E., McAnally, J., Pomajzl, C., Shelton, J. M., Richardson, J. A., et al. (2004) · Cell · doi:10.1016/j.cell.2004.10.024 · Cited by 804
Stat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790
Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression
Lagger, G., O'Carroll, D., Rembold, M., Khier, H., Tischler, J., Weitzer, G., Schuettengruber, B., Hauser, C., Brunmeir, R., Jenuwein, T., et al. (2002) · The EMBO Journal · doi:10.1093/emboj/21.11.2672 · Cited by 760
Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731
Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation
Jeong, J.-W., Bae, M.-K., Ahn, M.-Y., Kim, S.-H., Sohn, T.-K., Bae, M.-H., Yoo, M.-A., Song, E. J., Lee, K.-J., & Kim, K.-W. (2002) · Cell · doi:10.1016/s0092-8674(02)01085-1 · Cited by 716
Histone deacetylase inhibitors: Potential in cancer therapy
Marks, P. A., & Xu, W. ‐. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22185 · Cited by 712
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility
Montgomery, R. L., Davis, C. A., Potthoff, M. J., Haberland, M., Fielitz, J., Qi, X., Hill, J. A., Richardson, J. A., & Olson, E. N. (2007) · Genes & Development · doi:10.1101/gad.1563807 · Cited by 712
Regulation of activity of the transcription factor GATA-1 by acetylation
Boyes, J., Byfield, P., Nakatani, Y., & Ogryzko, V. (1998) · Nature · doi:10.1038/25166 · Cited by 694
Regulation of E2F1 activity by acetylation
Martínez-Balbás, M. A., Bauer, U.-M., Nielsen, S. J., Brehm, A., & Kouzarides, T. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.662 · Cited by 671
Acetylation of non-histone proteins modulates cellular signalling at multiple levels
Spange, S., Wagner, T., Heinzel, T., & Krämer, O. H. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.027 · Cited by 664
Histone deacetylases, transcriptional control, and cancer
Cress, W. D., & Seto, E. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<1::aid-jcp1>3.0.co;2-7 · Cited by 621
Chang, S., McKinsey, T. A., Zhang, C. L., Richardson, J. A., Hill, J. A., & Olson, E. N. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8467-8476.2004 · Cited by 613
Acetylation of the C Terminus of Ku70 by CBP and PCAF Controls Bax-Mediated Apoptosis
Cohen, H. Y., Lavu, S., Bitterman, K. J., Hekking, B., Imahiyerobo, T. A., Miller, C., Frye, R., Ploegh, H., Kessler, B. M., & Sinclair, D. A. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00094-2 · Cited by 578
Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575
MDM2–HDAC1-mediated deacetylation of p53 is required for its degradation
Ito, A., Kawaguchi, Y., Lai, C., Kovacs, J. J., Higashimoto, Y., Appella, E., & Yao, T. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf616 · Cited by 570
(2011) · PubMed Central · Cited by 560
Tanner, K. G., Landry, J., Sternglanz, R., & Denu, J. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.250422697 · Cited by 555
Post-activation Turn-off of NF-κB-dependent Transcription Is Regulated by Acetylation of p65
Kiernan, R., Brès, V., Ng, R. W. M., Coudart, M.-P., El Messaoudi, S., Sardet, C., Jin, D.-Y., Emiliani, S., & Benkirane, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209572200 · Cited by 535
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K.-P., & Göttlicher, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00114-x · Cited by 525
Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 509
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
Tumor-Associated Macrophages Press the Angiogenic Switch in Breast Cancer
Lin, E. Y., & Pollard, J. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0912 · Cited by 463
Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., et al. (2008) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 459
Histone Deacetylase 7 Maintains Vascular Integrity by Repressing Matrix Metalloproteinase 10
Chang, S., Young, B. D., Li, S., Qi, X., Richardson, J. A., & Olson, E. N. (2006) · Cell · doi:10.1016/j.cell.2006.05.040 · Cited by 453
Control of Cardiac Growth by Histone Acetylation/Deacetylation
Backs, J., & Olson, E. N. (2006) · Circulation Research · doi:10.1161/01.res.0000197782.21444.8f · Cited by 440
Regulation of Transcription Factor YY1 by Acetylation and Deacetylation
Yao, Y.-L., Yang, W.-M., & Seto, E. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.17.5979-5991.2001 · Cited by 434
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo
Luo, J., Li, M., Tang, Y., Laszkowska, M., Roeder, R. G., & Gu, W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308762101 · Cited by 422
Fu, M., Wang, C., Reutens, A. T., Wang, J., Angeletti, R. H., Siconolfi-Baez, L., Ogryzko, V., Avantaggiati, M.-L., & Pestell, R. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000660200 · Cited by 409
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy
Cao, D. J., Wang, Z. V., Battiprolu, P. K., Jiang, N., Morales, C. R., Kong, Y., Rothermel, B. A., Gillette, T. G., & Hill, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015081108 · Cited by 405
Byrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 398
Chemical mechanisms of histone lysine and arginine modifications
Smith, B. C., & Denu, J. M. (2009) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2008.06.005 · Cited by 390 · cited 2×
“This neutralizes the positive charge of the histone tails and reduces the affinity of histones for the negatively charged DNA backbone, thereby loosening the structure of the chromatin.(6,8) This enables the transcriptional machinery to access the DNA and enhances gene transcription.”
Soriano, A. O., Yang, H., Faderl, S., Estrov, Z., Giles, F., Ravandi, F., Cortes, J., Wierda, W. G., Ouzounian, S., Quezada, A., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078576 · Cited by 390
Control of Smad7 Stability by Competition between Acetylation and Ubiquitination
Grönroos, E., Hellman, U., Heldin, C.-H., & Ericsson, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00639-1 · Cited by 383
Wang, C., Fu, M., Angeletti, R. H., Siconolfi-Baez, L., Reutens, A. T., Albanese, C., Lisanti, M. P., Katzenellenbogen, B. S., Kato, S., Hopp, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100800200 · Cited by 366
Maintenance of cardiac energy metabolism by histone deacetylase 3 in mice
Montgomery, R. L., Potthoff, M. J., Haberland, M., Qi, X., Matsuzaki, S., Humphries, K. M., Richardson, J. A., Bassel-Duby, R., & Olson, E. N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35847 · Cited by 362
Acetylation of MyoD Directed by PCAF Is Necessary for the Execution of the Muscle Program
Sartorelli, V., Puri, P. L., Hamamori, Y., Ogryzko, V., Chung, G., Nakatani, Y., Wang, J. Y. J., & Kedes, L. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80383-4 · Cited by 356
Clinical Studies of Histone Deacetylase Inhibitors
Prince, H. M., Bishton, M. J., & Harrison, S. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2785 · Cited by 356
The c-MYC Oncoprotein Is a Substrate of the Acetyltransferases hGCN5/PCAF and TIP60
Patel, J. H., Du, Y., Ard, P. G., Phillips, C., Carella, B., Chen, C.-J., Rakowski, C., Chatterjee, C., Lieberman, P. M., Lane, W. S., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10826-10834.2004 · Cited by 354
Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases
Hu, E., Dul, E., Sung, C.-M., Chen, Z., Kirkpatrick, R., Zhang, G.-F., Johanson, K., Liu, R., Lago, A., Hofmann, G., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.055541 · Cited by 347
Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues
Choi, J., Kwon, H. J., Yoon, B., Kim, J., Han, S. U., Joo, H. J., & Kim, D. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02153.x · Cited by 346
Zhang, W., & Bieker, J. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.17.9855 · Cited by 342
HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation
Parmigiani, R. B., Xu, W. S., Venta-Perez, G., Erdjument-Bromage, H., Yaneva, M., Tempst, P., & Marks, P. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803749105 · Cited by 321
Acetylation of HMG I(Y) by CBP Turns off IFNβ Expression by Disrupting the Enhanceosome
Munshi, N., Merika, M., Yie, J., Senger, K., Chen, G., & Thanos, D. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80145-8 · Cited by 321
Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia
Blum, W., Klisovic, R. B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4169 · Cited by 315
Chromatin remodelling beyond transcription: the INO80 and SWR1 complexes
Morrison, A. J., & Shen, X. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2693 · Cited by 311
Gaughan, L., Logan, I. R., Cook, S., Neal, D. E., & Robson, C. N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203423200 · Cited by 310
Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., Hamaguchi, M., Hara, Y., Kobayashi, S., & Iwase, H. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-6001-1 · Cited by 305
The role of human bromodomains in chromatin biology and gene transcription.
Sánchez, R., & Zhou, M. (2009) · PubMed · Cited by 298
HDAC6 Expression Is Correlated with Better Survival in Breast Cancer
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Omoto, Y., Ando, Y., Mita, K., Hamaguchi, M., Hayashi, S.-I., & Iwase, H. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0455 · Cited by 293
Sandor, V, Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M. V., & Bates, S. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1327 · Cited by 290
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
Weller, M., Gorlia, T., Cairncross, J. G., van den Bent, M. J., Mason, W., Belanger, K., Brandes, A. A., Bogdahn, U., Macdonald, D. R., Forsyth, P., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f02e1 · Cited by 290
Gojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., Tidwell, M. L., Greer, J., Chung, E. J., Lee, M.-J., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021873 · Cited by 281
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Marks, P. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.510514 · Cited by 281
Wang, R., Cherukuri, P., & Luo, J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413930200 · Cited by 275
Regulation of p53 responses by post-translational modifications
Xu, Y. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401182 · Cited by 265
Kong, X., Lin, Z., Liang, D., Fath, D., Sang, N., & Caro, J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2019-2028.2006 · Cited by 258
Candelaria, M., Gallardo-Rincón, D., Arce, C., Cetina, L., Aguilar-Ponce, J. L., Arrieta, Ó., González-Fierro, A., Chávez-Blanco, A., de la Cruz-Hernández, E., Camargo, M. F., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm204 · Cited by 252
Histone deacetylase inhibitors: Signalling towards p21cip1/waf1
Ocker, M., & Schneider-Stock, R. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.001 · Cited by 250
Zhao, Y., Tan, J., Zhuang, L., Jiang, X., Liu, E. T., & Yu, Q. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505585102 · Cited by 246
Class IIa histone deacetylases: regulating the regulators
Martin, M., Kettmann, R., & Dequiedt, F. (2007) · Oncogene · doi:10.1038/sj.onc.1210613 · Cited by 244
Duan, H., Heckman, C. A., & Boxer, L. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.5.1608-1619.2005 · Cited by 242
Luu, T. H., Morgan, R. J., Leong, L., Lim, D., McNamara, M., Portnow, J., Frankel, P., Smith, D. D., Doroshow, J. H., Gandara, D. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0122 · Cited by 237
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Adimoolam, S., Sirisawad, M., Chen, J., Thiemann, P., Ford, J. M., & Buggy, J. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707828104 · Cited by 236
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W. M., Miller, W. H., Rousseau, C., Kalita, A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-115873 · Cited by 233
E2F Family Members Are Differentially Regulated by Reversible Acetylation
Marzio, G., Wagener, C., Gutierrez, M. I., Cartwright, P., Helin, K., & Giacca, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.10887 · Cited by 231
Histone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical Trials
Ma, X., Ezzeldin, H. H., & Diasio, R. B. (2009) · Drugs · doi:10.2165/11315680-000000000-00000 · Cited by 227
Kawai, H., Li, H., Avraham, S., Jiang, S., & Avraham, H. K. (2003) · International Journal of Cancer · doi:10.1002/ijc.11403 · Cited by 226
Modesitt, S. C., Sill, M., Hoffman, J. S., & Bender, D. P. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.009 · Cited by 225
Epigenetic control of skull morphogenesis by histone deacetylase 8
Haberland, M., Mokalled, M. H., Montgomery, R. L., & Olson, E. N. (2009) · Genes & Development · doi:10.1101/gad.1809209 · Cited by 219
Münster, P., Marchion, D., Bicaku, E., Schmitt, M., Lee, J. H., DeConti, R., Simon, G., Fishman, M., Minton, S., Garrett, C., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.6165 · Cited by 216
Kirschbaum, M., Frankel, P., Popplewell, L., Zain, J., Delioukina, M., Pullarkat, V., Matsuoka, D., Pulone, B., Rotter, A. J., Espinoza-Delgado, I., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.1398 · Cited by 213
Jin, Y.-H., Jeon, E.-J., Li, Q.-L., Lee, Y. H., Choi, J.-K., Kim, W.-J., Lee, K.-Y., & Bae, S.-C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313120200 · Cited by 211
Coordination of a Transcriptional Switch by HMGI(Y) Acetylation
Munshi, N., Agalioti, T., Lomvardas, S., Merika, M., Chen, G., & Thanos, D. (2001) · Science · doi:10.1126/science.293.5532.1133 · Cited by 206
A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer
Marshall, J. L., Rizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M. H., Figg, W. D., Wainer, I., Chaissang, C., Zhaoyang Li, M., et al. (2002) · Journal of Experimental Therapeutics and Oncology · doi:10.1046/j.1359-4117.2002.01039.x · Cited by 204
Namdar, M., Perez, G., Ngo, L., & Marks, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013754107 · Cited by 203
Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions
Marks, P. A. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.008 · Cited by 187
Atmaca, A., Al-Batran, S.-E., Maurer, A., Neumann, A., Heinzel, T., Hentsch, B., Schwarz, S. E., Hövelmann, S., Göttlicher, M., Knuth, A., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603851 · Cited by 183
Zhang, W., Kadam, S., Emerson, B. M., & Bieker, J. J. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.7.2413-2422.2001 · Cited by 182
HDAC inhibitors enhance the apoptosis-inducing potential of TRAIL in breast carcinoma
Singh, T. R., Shankar, S., & Srivastava, R. K. (2005) · Oncogene · doi:10.1038/sj.onc.1208585 · Cited by 177
Acetylation of importin-α nuclear import factors by CBP/p300
Bannister, A. J., Miska, E. A., Görlich, D., & Kouzarides, T. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00445-0 · Cited by 176
Vansteenkiste, J., Van Cutsem, E., Dumez, H., Chen, C., Ricker, J. L., Randolph, S. S., & Schöffski, P. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9131-6 · Cited by 174
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation
Gaughan, L. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki141 · Cited by 174
Gore, L., Rothenberg, M. L., O'Bryant, C. L., Schultz, M. K., Sandler, A. B., Coffin, D., McCoy, C., Schott, A., Scholz, C., & Eckhardt, S. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1461 · Cited by 171
Fu, M., Wang, C., Wang, J., Zhang, X., Sakamaki, T., Yeung, Y. G., Chang, C., Hopp, T., Fuqua, S. A. W., Jaffray, E., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3373-3388.2002 · Cited by 171
Rada-Iglesias, A., Enroth, S., Ameur, A., Koch, C. M., Clelland, G. K., Respuela-Alonso, P., Wilcox, S., Dovey, O. M., Ellis, P. D., Langford, C. F., et al. (2007) · Genome Research · doi:10.1101/gr.5540007 · Cited by 169
Blumenschein, G. R., Kies, M. S., Papadimitrakopoulou, V. A., Lu, C., Kumar, A. J., Ricker, J. L., Chiao, J. H., Chen, C., & Frankel, S. R. (2008) · Investigational New Drugs · doi:10.1007/s10637-007-9075-2 · Cited by 167
Bogaard, H., Mizuno, S., Hussaini, A. A. A., Toldo, S., Abbate, A., Kraskauskas, D., Kasper, M., Natarajan, R., & Voelkel, N. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1106oc · Cited by 167
Transcriptional regulation in acute promyelocytic leukemia
Lin, R. J., Sternsdorf, T., Tini, M., & Evans, R. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204853 · Cited by 155
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2V617F
Guerini, V., Barbui, V., Spinelli, O., Salvi, A., Dellacasa, C. M., Carobbio, A., Introna, M., Barbui, T., Golay, J., & Rambaldi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2405049 · Cited by 153
A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer
Stadler, W. M., Margolin, K. A., Ferber, S., McCulloch, W. F., & Thompson, J. A. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.018 · Cited by 151
Traynor, A. M., Dubey, S., Eickhoff, J. C., Kolesar, J., Schell, K. A., Huie, M. S., Groteluschen, D. L., Marcotte, S. M., Hallahan, C. M., Weeks, H., et al. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181952478 · Cited by 140
Romidepsin for the treatment of cutaneous T-cell lymphoma
Campàs-Moya, C. (2009) · Drugs of today · doi:10.1358/dot.2009.45.11.1437052 · Cited by 138
Chatting histone modifications in mammals
Izzo, A., & Schneider, R. (2010) · Briefings in Functional Genomics · doi:10.1093/bfgp/elq024 · Cited by 137
Srivastava, R. K., Kurzrock, R., & Shankar, S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0582 · Cited by 135
Kummar, S., Gutierrez, M. E., Gardner, E. R., Donovan, E. A., Hwang, K., Chung, E. J., Lee, M.-J., Maynard, K., Kalnitskiy, M., Chen, A. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0791 · Cited by 132
Klimek, V. M., Fircanis, S., Maslak, P. G., Guernah, I., Baum, M., Wu, N. F., Panageas, K. S., Wright, J. J., Pandolfi, P. P., & Nimer, S. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0318 · Cited by 130
Acetylation of GATA‐3 affects T‐cell survival and homing to secondary lymphoid organs
Yamagata, T., Mitani, K., Oda, H., Suzuki, T., Honda, H., Asai, T., Maki, K., Nakamoto, T., & Hirai, H. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4676 · Cited by 121
Siu, L. L., Пили, Р., Durán, I., Messersmith, W. A., Chen, E. X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G. K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5730 · Cited by 119
Rubin, E. H., Agrawal, N. G. B., Friedman, E. J., Scott, P., Mazina, K. E., Sun, L., Du, L., Ricker, J. L., Frankel, S. R., Gottesdiener, K. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1802 · Cited by 115
Regulation of human SRY subcellular distribution by its acetylation/deacetylation
Thevenet, L., Méjean, C., Moniot, B., Bonneaud, N., Galéotti, N., Aldrian, G., Poulat, F., Berta, P., Benkirane, M., & Boizet‐Bonhoure, B. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600352 · Cited by 114
Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis
Zhang, Y., Adachi, M., Kawamura, R., & Imai, K. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401686 · Cited by 110
Fath, D. M., Kong, X.-G., Liang, D.-M., Lin, Z., Chou, A., Jiang, Y.-B., Fang, J., Caro, J., & Sang, N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600456200 · Cited by 103
Functional regulation of GATA-2 by acetylation
Hayakawa, F., Towatari, M., Ozawa, Y., Tomita, A., Privalsky, M. L., & Saito, H. (2003) · Journal of Leukocyte Biology · doi:10.1189/jlb.0603389 · Cited by 103
Discovery of histone deacetylase 8 selective inhibitors
Tang, W., Luo, T., Greenberg, E. F., Bradner, J. E., & Schreiber, S. L. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.134 · Cited by 98
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2007) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70818-x · Cited by 97
Cho, Y. K., Eom, G. H., Kee, H. J., Kim, H.-S., Choi, W.-Y., Nam, K. I., Ma, J. S., & Kook, H. Y. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0580 · Cited by 97
Autophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells
Rikiishi, H. (2011) · BioMed Research International · doi:10.1155/2011/830260 · Cited by 94
Attenuated DNA Damage Repair by Trichostatin A through BRCA1 Suppression
Zhang, Y., Carr, T., Dimtchev, A., Zaer, N., Dritschilo, A., & Jung, M. (2007) · Radiation Research · doi:10.1667/rr0811.1 · Cited by 93
Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas
Khan, O. A., & Thangue, N. B. L. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1238 · Cited by 88
Santos, M. D. L., Zambrano, A., & Aranda, A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0623 · Cited by 83
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor
Sánchez‐González, B., Yang, H., Bueso-Ramos, C., Hoshino, K., Quintás‐Cardama, A., Richon, V. M., & Garcia‐Manero, G. (2006) · Blood · doi:10.1182/blood-2005-09-008086 · Cited by 79
Karagiannis, T. C., Kn, H., & El‐Osta, A. (2007) · Oncogene · doi:10.1038/sj.onc.1210174 · Cited by 75
Schneider‐Stock, R., & Ocker, M. (2007) · PubMed · Cited by 61
Deacetylase inhibitors - focus on non-histone targets and effects
Ocker, M. (2010) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v1.i5.55 · Cited by 60
Dual Roles of Histone Deacetylases in the Control of Cardiac Growth
McKinsey, T. A., & Olson, E. N. (2004) · Novartis Foundation symposium · doi:10.1002/0470862637.ch9 · Cited by 57
Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes
Karagiannis, T. C., Lin, A. J., Ververis, K., Chang, L., Tang, M. M., Okabe, J., & El‐Osta, A. (2010) · Aging · doi:10.18632/aging.100203 · Cited by 55
Kaipananickal, H., Karagiannis, T. C., Chow, M. Z. Y., & El‐Osta, A. (2008) · Cell Cycle · doi:10.4161/cc.7.4.5405 · Cited by 50
Karagiannis, T. C., Kaipananickal, H., & El‐Osta, A. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.1922 · Cited by 50
Barbetti, V., Gozzini, A., Rovida, E., Morandi, A., Spinelli, E., Fossati, G., Mascagni, P., Lübbert, M., Sbarba, P. D., & Santini, V. (2007) · Oncogene · doi:10.1038/sj.onc.1210820 · Cited by 46
Chromatin modifications and DNA double-strand breaks: the current state of play
Karagiannis, T. C., & El‐Osta, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404478 · Cited by 36
Potential non-oncological applications of histone deacetylase inhibitors.
Ververis, K., & Karagiannis, T. C. (2011) · Europe PMC (PubMed Central) · Cited by 29
Santos, M. D. L., Zambrano, A., Sánchez‐Pacheco, A., & Aranda, A. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0151 · Cited by 29
Lech‐Marańda, E., Robak, E., Korycka, A., & Robak, T. (2007) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955707782110178 · Cited by 26
Lührs, H., Hock, R., Schauber, J., Weihrauch, M., Harrer, M., Melcher, R., Scheppach, W. M., Bustin, M., & Menzel, T. (2001) · International Journal of Cancer · doi:10.1002/ijc.10098 · Cited by 25
Promising antitumor activity with MGCD0103, a novel isotype-selective histone deacetylase inhibitor
Tourneau, C. L., & Siu, L. L. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.8.1247 · Cited by 24
Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes
Ververis, K., Rodd, A. L., Tang, M. M., El‐Osta, A., & Karagiannis, T. C. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0727-1 · Cited by 21
Briggs, B., Ververis, K., Rodd, A. L., Foong, L. J. L., Silva, F. M. D., & Karagiannis, T. C. (2011) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2011.02.022 · Cited by 11
Cited by
Hull, E. E., Montgomery, M. R., & Leyva, K. J. (2016) · BioMed Research International · doi:10.1155/2016/8797206 · Cited by 313
Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology
Shah, R. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0773-9 · Cited by 197
HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: Where do we stand?
Whittle, N., & Singewald, N. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130233 · Cited by 117
Varela, R. B., Valvassori, S. S., Lopes-Borges, J., Mariot, E., Dal-Pont, G. C., Amboni, R. T., Bianchini, G., & Quevedo, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.11.003 · Cited by 115
Légaré, S., & Basik, M. (2016) · Molecular Endocrinology · doi:10.1210/me.2016-1072 · Cited by 63
Metadata
- Authors
- Licciardi, P., Ververis, Hiong, & Karagiannis
- Venue
- Biologics: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2013-02
- Volume
- 7
- Pages
- 47
- ISSN
- 1177-5475 (ISSN-L)
- OpenAlex
- W2083124842
- Cited by
- 274
- References
- 153
- FWCI
- 15.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.